Skip to main content
. 2021 Feb 18;12:636324. doi: 10.3389/fphar.2021.636324

TABLE 3.

Pharmacokinetic (PK) properties of larotinib after oral administration of single and multiple doses of 50-, 100-, 150-, 220-, 300-, 350- and 400-mg larotinib mesylate tablets.

PK Variables Dosage (mg)
50 mg 100 mg 150 mg 220 mg 300 mg 350 mg 400 mg
Single oral administration No 3 3 3 3 6 3 3
Tmax, median (min–max), h 6.00 (5.00–6.00) 5.00 (3.00–6.00) 5.00 (2.00–5.00) 5.00 (2.00–5.00) 5.00 (2.00–5.00) 3.50 (2.00–5.00) 5.00 (3.00–6.00)
Cmax, mean (min–max), ng/mL 17.42 (15.96–18.70) 64.08 (48.32–84.51) 149.9 (128.4–174.9) 278.0 (169.0–437.0) 267.3 (106.8–401.0) 299.8 (152.1–590.4) 354.3 (76.53–678.8)
AUC0-24, mean (min–max), h*ng/mL 244.7 (229.2–254.1) 652.7 (506.0–822.1) 1987 (1,507–2,705) 3,104 (2,384–4,212) 2,690 (1,153–4,397) 3,236 (1741–5,416) 3,973 (1,031–6,848)
AUC0-t, mean (min–max), h*ng/mL 634.9 (561.0–691.4) 1,243 (1,009–1,446) 4,781 (3,586–6,799) 6,359 (5,421–7977) 4,885 (2,208–8,615) 6,120 (3,871–9,164) 7435 (2,119–11,572)
AUC0-∞, mean (min–max), h*ng/mL 816.6 (701.3–923.0) 1,390 (1,101–1,597) 5,662 (3,938–8,198) 8,093 (6,503–9,065) 5,554 (2,576–9,951) 6,832 (4,777–9,670) 9,088 (2,747–13,379)
T1/2, mean (min–max), h 56.71 (56.02–57.42) 43.86 (35.81–52.38) 39.29 (35.34–45.71) 68.20 (44.62–99.19) 46.20 (39.75–52.26) 44.61 (32.56–56.39) 68.60 (58.44–76.26)
Vz/F, mean (min–max), L 5,071 (4,487–5,831) 4,583 (3,919–5,138) 1,651 (971.9–2040) 2,715 (1,562–3,614) 4,345 (1982–8,779) 3,802 (1700–5,960) 7408 (2,521–16,020)
CL/F, mean (min–max), L/h 62.01 (54.17–71.3) 73.81 (62.61–90.83) 29.11 (18.30–38.09) 27.79 (24.27–33.83) 63.76 (30.15–116.4) 55.78 (36.19–73.27) 70.47 (29.90–145.6)
Multiple oral administration No 3 3 3 3 5 3 3
Tmax,ss, median (min–max), h 5.00 (5.00–6.00) 5.00 (5.00–5.00) 5.00 (2.00–5.00) 6.00 (2.00–12.00) 5.00 (1.00–6.00) 5.00 (4.00–6.00) 6.00 (4.00–6.00)
Cmax,ss, mean (min–max), ng/mL 67.50 (65.34–70.90) 131.36 (85.19–185.4) 371.37 (318.6–470.7) 552.6 (405.4–804.4) 437.9 (300.3–550.7) 694.7 (476.3–840.3) 844.8 (637.1–1,087)
AUCτ,ss, mean (min–max), h*ng/mL 1,216 (1,029–1,334) 1967 (1,183–2,756) 6,502 (5,277–8,553) 10,303 (8,707–13,353) 7260 (5,889–8,237) 13,155 (9,608–15,933) 16,081 (12,503–19,042)
AUC0-t,ss, mean (min–max), h*ng/mL 3,573 (3,009–4,374) 4,479 (2,803–6,271) 18,237 (15,139–23,862) 30,159 (26,097–34,650) 17,925 (13,660–21,285) 35,937 (28,950–44,107) 44,997 (32,935–54,565)
AUC0-∞,ss, mean (min–max), h*ng/mL 4,922 (3,947–6,655) 5,196 (3,387–7244) 24,555 (19,828–33,984) 43,641 (36,075–47,906) 22,592 (16,340–28,368) 47,327 (39,584–60,144) 70,416 (50,669–96,144)
T1/2,ss, mean (min–max), h 61.20 (50.41–72.73) 44.79 (42.04–49.22) 61.21 (55.71–68.70) 75.66 (66.11–83.41) 54.34 (47.58–67.58) 58.60 (50.04–64.28) 87.05 (66.36–102.4)
Vz/F,ss, mean (min–max), L 921.4 (788.3–1,097) 1,396 (837.2–2097) 563.7 (437.5–646.3) 552.9 (513.1–581.7) 1,061 (904.9–1,260) 640.7 (539.6–784.4) 753.7 (594.3–1,052)
CL/F,ss, mean (min–max), L/h 10.73 (7.513–12.58) 21.17 (13.80–29.53) 6.512 (4.414–7.565) 5.126 (4.592–6.098) 13.91 (10.58–18.36) 7.648 (5.819–8.842) 6.087 (4.160–7.894)
R1 (min-max) 4.998 (4.048–5.817) 3.231 (1.439–4.376) 3.302 (3.162–3.502) 3.360 (3.170–3.652) 3.235 (1.713–5.108) 4.639 (2.942–5.519) 6.345 (2.781–12.12)
R2 (min-max) 3.885 (3.711–4.152) 2.308 (1.008–3.837) 2.466 (2.177–2.691) 2.068 (1.841–2.399) 1.888 (1.114–2.813) 2.757 (1.423–3.716) 4.187 (1.602–8.325)

ss = steady state; SD = standard deviation; Tmax = time to peak plasma concentration; Cmax = peak plasma concentration; AUC = area under the plasma concentration curve; T1/2 = terminal elimination halt-life; Vz/F = apparent volume of distribution; CL/F = apparent clearance; R1 = AUCτ,cycle1/AUC0–24h,cycle0; R2 = Cmax, cycle1/Cmax, cycle0.